Disruption of endogenous circadian rhythms has been shown to increase the risk of developing type 2 diabetes, suggesting that circadian genes might play a role in determining disease susceptibility. We present the results of a pilot study investigating the association between type 2 diabetes and selected single nucleotide polymorphisms (SNPs) in/near nine circadian genes. The variants were chosen based on their previously reported association with prostate cancer, a disease that has been suggested to have a genetic link with type 2 diabetes through a number of shared inherited risk determinants.
The pilot study was performed using two genetically homogeneous Punjabi cohorts, one resident in the United Kingdom and one indigenous to Pakistan. Subjects with (N = 1732) and without (N = 1780) type 2 diabetes were genotyped for thirteen circadian variants using a competitive allele-specific polymerase chain reaction method. Associations between the SNPs and type 2 diabetes were investigated using logistic regression. The results were also combined with in silico data from other South Asian datasets (SAT2D consortium) and white European cohorts (DIAGRAM+) using meta-analysis. The rs7602358G allele near PER2 was negatively associated with type 2 diabetes in our Punjabi cohorts (combined odds ratio [OR] = 0.75 [0.66–0.86], p = 3.18×10−5), while the BMAL1 rs11022775T allele was associated with an increased risk of the disease (combined OR = 1.22 [1.07–1.39], p = 0.003). Neither of these associations was replicated in the SAT2D or DIAGRAM+ datasets, however. Meta-analysis of all the cohorts identified disease associations with two variants, rs2292912 in CRY2 and rs12315175 near CRY1, although statistical significance was nominal (combined OR = 1.05 [1.01–1.08], p = 0.008 and OR = 0.95 [0.91–0.99], p = 0.015 respectively).
None of the selected circadian gene variants was associated with type 2 diabetes with study-wide significance after meta-analysis. The nominal association observed with the CRY2 SNP, however, complements previous findings and confirms a role for this locus in disease susceptibility.
Citation: Kelly MA, Rees SD, Hydrie MZI, Shera AS, Bellary S, O’Hare JP, et al. (2012) Circadian Gene Variants and Susceptibility to Type 2 Diabetes: A Pilot Study. PLoS ONE 7(4): e32670. doi:10.1371/journal.pone.0032670
Editor: Rui Medeiros, IPO, Inst Port Oncology, Portugal
Received: December 12, 2011; Accepted: February 2, 2012; Published: April 2, 2012
Copyright: © 2012 Kelly et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Collection of DNA and clinical data from the Pakistan-resident population was supported by Diabetes United Kingdom (project number 07/0003512, www.diabetes.org.uk). The United Kingdom Asian Diabetes Study (UKADS) was supported by Pfizer, Sanofi-Aventis, Servier Laboratories United Kingdom, Merck Sharp and Dohme/Schering-Plough, Takeda UK, Roche, Merck Pharma, Daiichi-Sankyo United Kingdom, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Bristol-Myers Squibb, Solvay Health Care and Assurance Medical Society United Kingdom. Funding for the genetic analyses was provided by Eli Lilly. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: We have read the journal’s policy and have the following conflicts. This study was partly funded by Eli Lilly. Professor Sudhesh Kumar has received lecture fees and research funding from Eli Lilly. Professor Anthony Barnett has received honoraria from Eli Lilly for lectures and advisory work, and has received research funding from Eli Lilly. Dr. Shahrad Taheri has received educational funding support from Eli Lilly. The United Kingdom Asian Diabetes Study was supported by Pfizer, Sanofi-Aventis, Servier Laboratories United Kingdom, Merck Sharp & Dohme/Schering-Plough, Takeda United Kingdom, Roche, Merck Pharma, Daiichi-Sankyo United Kingdom, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Bristol-Myers Squibb, Solvay Health Care and Assurance Medical Society UK. Professor Barnett has received research funding and honoraria for lecturing and advisory work from these sources. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
Accumulating evidence suggests that dysregulation of the circadian clock plays an important role in glucose homeostasis and the development of type 2 diabetes. Cross-sectional and prospective studies have shown that voluntary sleep curtailment to 6 hours or less per day is associated with increased fasting glucose levels, hyperinsulinaemia and reduced insulin sensitivity, leading to an increased risk of diabetes , . Laboratory-imposed circadian desynchrony, resulting in misalignment between behavioural cycles (such as sleep/wake and fasting/feeding) and endogenous circadian rhythm, has also been shown to result in increased postprandial glucose and insulin levels, increased mean arterial blood pressure and decreased leptin levels . These metabolic disturbances could explain the increased risk of diabetes, obesity and cardiovascular disease observed in shift-workers , .
Circadian rhythms are controlled and maintained by transcription-translation-based networks of positive and negative feedback loops that oscillate with 24-hour rhythmicity . A recent study in mice showed that mutations in the genes encoding the CLOCK and BMAL1 transcription factors resulted in impaired glucose tolerance, reduced insulin secretion and defects in islet development, while ablation of the endogenous pancreatic clock resulted in the development of diabetes . Variants of circadian genes, such as MTNR1B, CRY2, PER3, PER2 and BMAL1, have recently been implicated as determinants of fasting glucose levels and/or diabetes risk in humans –, while single nucleotide polymorphisms (SNPs) in the CLOCK and PER2 genes were reported to be associated with measures of obesity [13,14]. Further investigations of circadian genes as risk markers for metabolic disease are therefore warranted.
We aimed to investigate the role of circadian gene variants as susceptibility determinants for type 2 diabetes. Before embarking on a comprehensive tag SNP analysis, however, we carried out a pilot study of selected variants chosen on the basis of their previously reported association with prostate cancer, another condition where risk has been shown to be modified by circadian misalignment . The relationship between type 2 diabetes and prostate cancer is controversial. Although a number of studies have suggested that diabetic men appear to be less prone to prostate cancer than non-diabetic men (relative risk = 0.84 from a recent meta-analysis ), this negative correlation between the diseases has not been observed in all populations. Despite this epidemiological inconsistency, there is compelling evidence of a genetic link between the two diseases. Variants in HNF1B, UCP2, SLC2A2, IGF2BP2, TCF7L2 and CAPN10 have been shown to predispose to type 2 diabetes and protect against prostate cancer or vice versa , . A recent study also reported an inverse association between the risk of prostate cancer and a genetic risk score for type 2 diabetes , although a subsequent study of a subset of 17 diabetes-associated SNPs in a multiethnic cohort found no evidence of an impact on prostate cancer risk . The JAZF1 gene has been implicated in both disorders, although the cancer-protective and diabetes-predisposing effects are mediated by different SNPs . Similarly, independent association signals for the two diseases have been identified in the THADA gene by genome-wide association studies (GWAS) , . A recent report by Zhu et al  suggested that twelve variants in, or close to, nine circadian-related genes were associated with overall prostate cancer risk, or risk of more or less aggressive disease. The aim of our pilot study was to determine whether these SNPs also influence the risk of type 2 diabetes.
Materials and Methods
Informed written consent was obtained from all participants and the study was approved by the Birmingham East, North and Solihull Research Ethics Committee (for participants resident in the United Kingdom) and the Baqai Institute of Diabetology and Endocrinology Institutional Review Board (for participants resident in Pakistan).
The study was performed using two populations of South Asian origin. UK-resident subjects (892 with type 2 diabetes, 471 normoglycaemic individuals) were recruited from Birmingham and Coventry as part of the United Kingdom Asian Diabetes Study (UKADS)  (UKADS registered clinical trial number; ISRCTN38297969). Pakistan-based subjects (840 with type 2 diabetes, 1309 normoglycaemic individuals) were recruited from the Mirpur region of Azad Kashmir (Diabetes Genetics in Pakistan study, DGP). All individuals were of Punjabi ancestry and originated predominantly from Mirpur. Diagnosis of type 2 diabetes was established using World Health Organisation criteria . Normoglycaemia was defined as random blood glucose <7mmol/l in the UKADS control subjects and fasting whole blood glucose ≤5.6mmol/l in the DGP control subjects. Details of the study subjects have been published previously .
The subjects (N = 3512) were genotyped for selected circadian gene variants using the KASPar method (KBiosciences, Hoddesdon, UK). The twelve SNPs previously associated with prostate cancer were investigated (CLOCK, rs11133373; BMAL1, rs7950226; PER1, rs885747 and rs2289591; PER2, rs7602358; PER3, rs1012477; CRY1, rs12315175; CRY2, rs2292912; CSNK1E, rs1534891; NPAS2, rs1369481, rs895521 and rs17024926). In addition we also genotyped for BMAL1 rs11022775, as this has previously been shown to be part of a susceptibility haplotype for type 2 diabetes along with rs7950226 . For all SNPs, genotyping success rates were >96% and error rates in 384 duplicate samples were <0.6%.
Statistical analysis was performed using STATA IC (version 10.1)(Stata Corporation, College Station, TX, USA). Genotype frequencies for each SNP were checked for deviation from Hardy-Weinberg equilibrium in the normoglycaemic subjects using an exact test. The association between SNPs and type 2 diabetes was tested using logistic regression, adjusting for age and sex. The indigenous and migrant populations were analysed separately in the first instance; odds ratio (OR) values were then combined using inverse variance weighted meta-analysis, implemented in METAN. A study-wide significance threshold of p<0.0039 was applied to the analysis of the 13 SNPs in these datasets. To improve sample size and get a truer picture of the impact of the SNPs on disease risk, meta-analysis was used to combine data from the pilot study with summary statistics from the GWA phases of the expanded DIAbetes Genetics Replication And Meta-analysis (DIAGRAM+) study  and the South Asian Type 2 Diabetes (SAT2D) study . The DIAGRAM+ cohort comprised 8,130 cases with type 2 diabetes and 38,987 control subjects of white European ancestry, while the SAT2D dataset consisted of 5,561 South Asian individuals with type 2 diabetes and 14,458 ethnically-matched control subjects. Heterogeneity of OR values between the UKADS and DGP study populations, and between the combined UKADS/DGP dataset, SAT2D and DIAGRAM+ cohorts, was assessed using Cochran’s Q statistic. Haplotype analysis for the BMAL1 locus was performed using a logistic regression framework implemented in PLINK .
The clinical characteristics of the UKADS/DGP study subjects are shown in Table S1. None of the studied SNPs deviated significantly from Hardy-Weinberg equilibrium in the control groups from these cohorts after correction for the number of tests performed. Table 1 shows the OR values (with 95% confidence intervals) and significance values for the association of type 2 diabetes with each of the 13 studied SNPs in our South Asian populations, along with the DIAGRAM+ and SAT2D cohorts. OR values did not differ significantly between the indigenous and migrant Punjabi populations in our study; therefore results are presented for the combined UKADS/DGP dataset. Sex-specific analysis of this cohort showed no significant differences in OR values between males and females (Table S2).
Two of the variants were associated with type 2 diabetes in the UKADS/DGP cohort at a study-wide significant level (Table 1). The minor allele (T) of BMAL1 rs11022775 was associated with susceptibility to the disease (p = 0.003). The rs11022775T/rs7950226A BMAL1 haplotype was also nominally associated with an increased risk of diabetes in this cohort before correction for multiple testing (p = 0.007); this effect appeared to be driven by the rs11022775 SNP. In contrast, the minor allele (G) of rs7602358 near the PER2 locus appeared to confer protection against type 2 diabetes in both the UKADS (p = 0.003) and DGP (p = 0.004) datasets (combined cohort, p = 3.18×10−5). Neither of these observations was confirmed in the SAT2D or DIAGRAM+ datasets, however. The BMAL1 rs11022775 SNP was nominally associated with disease in the DIAGRAM+ cohort, but disease risk appeared to be conferred by the C allele, not T as seen in UKADS/DGP. No evidence of an association with rs7602358 was seen in the DIAGRAM+ or SAT2D datasets. In the latter cohort, two NPAS2 SNPs (rs1369481 and rs17024926) were associated with type 2 diabetes, the former with a p value of 3.78×10−4, but this was not replicated in the UKADS/DGP or DIAGRAM+ datasets (Table 1).
Meta-analysis of all the datasets failed to confirm the disease associations with the BMAL1 and PER2 variants. In contrast, type 2 diabetes was associated with rs12315175, close to the CRY1 gene, and rs2292912, located in the CRY2 gene (Table 1 and Figure 1), although statistical significance was nominal in both cases.
The pilot study of 13 circadian gene variants in two populations of Punjabi ancestry suggested a significantly protective influence of the G allele of the rs7602358 SNP, located upstream of the PER2 locus (OR = 0.75, p = 3.18×10−5). The association was consistent in independently ascertained indigenous and migrant populations, with almost identical effect sizes (DGP, OR = 0.77; UKADS, OR = 0.73), and was observed in both males and females (Table S2). Furthermore this SNP was more strongly associated with type 2 diabetes in the combined UKADS/DGP cohorts than most of the currently validated type 2 diabetes risk determinants, with the exception of the TCF7L2 rs7902346 variant , leading us to believe that the association might be genuine. This was not confirmed by the analysis of the DIAGRAM+ and SAT2D cohorts, however, which showed no evidence of a role for rs7602358 in disease risk. These findings suggest that we have either identified a false positive association or picked up a variant with a population-specific effect. It should be noted that the South Asians included in the SAT2D study were from different ethnic subgroups to those in the UKADS/DGP cohorts and this could contribute to the discrepancy between the observed effect sizes. The inconsistency in results could not be attributed to differences in minor allele frequency for rs7602358 as it was similar in all the datasets (Table S3).
The BMAL1 locus was associated with type 2 diabetes in our Punjabi populations, albeit with borderline significance. Our findings differed from those reported previously by Woon et al , who showed that the rs7950226A/rs11022775C haplotype was associated with an increased risk of diabetes in British families, with the former variant independently more strongly associated than the latter. In contrast, disease susceptibility in the UKADS/DGP cohort was associated with rs7950226A/rs11022775T and this effect appeared to be mediated entirely through rs11022775T. The borderline associations with BMAL1 variants seen in the UKADS/DGP and DIAGRAM+ datasets and the inconsistency between the results suggest that they are likely to be false positives, a conclusion borne out by the lack of association with either SNP in the meta-analysis.
The analysis of the SAT2D data showed two potentially interesting associations with the NPAS2 locus, with the rs1369481 variant achieving a reasonable level of significance (p = 3.78×10−4). As for the SNPs described above, however, this was not replicated in either of the other datasets and no consistent direction of effect was observed.
Although meta-analysis of the datasets did not confirm disease associations with the PER2 and BMAL1 variants, it did provide nominal evidence of associations with CRY2 rs2292912 and CRY1 rs12315175. The former SNP is located ~4.6 kb from rs11605924, which was reported to be associated with type 2 diabetes in the MAGIC study (p = 1.7×10−4), with a similar effect size (OR = 1.04) to that seen for rs2292912 in the current meta-analysis (OR = 1.05). These two variants are not in strong linkage disequilibrium (LD) (r2 = 0.3 in HapMap Data Release 27; www.hapmap.ncbi.nlm.nih.gov), suggesting that there might be two independent association signals for type 2 diabetes at this locus. The association with rs12315175 near CRY1 is a novel finding. Interestingly recent studies in mice have suggested a role for Cry1 in glucose homeostasis; hepatic overexpression of the protein was shown to lower blood glucose concentrations and improve insulin sensitivity in insulin-resistant db/db mice , while transgenic mice expressing a mutant form of Cry1 developed hyperglycaemia associated with an early-onset insulin-secretory defect . The role of CRY1 in human diabetes may therefore warrant further investigation.
It is interesting to note that the variants displaying significant disease associations in individual populations in our study appear to have opposite directions of effect on type 2 diabetes and prostate cancer; that is the minor alleles of the CRY2 and NPAS2 variants that appear to increase the risk of diabetes in one or more of our datasets are associated with a decreased risk of prostate cancer in the study of Zhu et al , while the putative diabetes-protective alleles near PER2 and CRY1 appear to confer an increased risk of prostate cancer. These findings are consistent with the inverse disease relationship reported by meta-analysis of epidemiological data . It should be noted, however, that none of the prostate cancer associations described by Zhu et al  achieved genome-wide significance and the variants are yet to be confirmed as genuine risk determinants for the disease.
As our pilot study investigated only selected circadian variants, we cannot exclude the possibility that other SNPs at these loci have an influence on disease susceptibility. It is unlikely that such an influence would be major, however, as we would expect this to have been picked up by the genome-wide association analysis of the DIAGRAM+ and SAT2D datasets , . Nevertheless it is possible that variants of these genes have a more modest effect, which did not reach the threshold for follow-up in these studies.
In conclusion our study has confirmed the association between type 2 diabetes and variants of the CRY2 gene and suggested a potential role for the CRY1 gene in disease development. Together with previous reports of associations between fasting glucose/diabetes and the MTNR1B and CRY2 loci , , our data support a role for the circadian clock in the regulation of glucose homeostasis.
Clinical characteristics of subjects stratified by study population, disease status and sex.
Sex-specific analysis of circadian gene variants in UKADS/DGP cohort.
Minor allele frequencies of circadian SNPs in UKADS/DGP, DIAGRAM + and SAT2D datasets.
The authors would like to thank all the participants in this study. We are grateful to Dr. Sri Bellary, Dr. Anthony Dixon, Ms. Shanaz Mughal, Mrs. Kam Johal and Mrs. Tahera Mehrali in the UK, and Dr. Asher Fawwad, Dr. Waheed Iqbal and Dr. Abdul Razzaq in Pakistan, for recruiting the study subjects and coordinating data collection. We also thank our collaborators in the DIAGRAM and SAT2D consortia (see below) for providing in silico data for meta-analysis, and Professor Mark McCarthy (MIM) and Dr John Chambers (JCC) for useful discussion during the preparation of the manuscript. The United Kingdom Asian Diabetes Study was conceived and managed by Professor Anthony Barnett, Professor Sudhesh Kumar and Dr Paul O’Hare.
Members of the DIAGRAM consortium:
Benjamin F Voight, Laura J Scott, Valgerdur Steinthorsdottir, Andrew P Morris, Christian Dina, Ryan P Welch, Eleftheria Zeggini, Cornelia Huth, Yurii S Aulchenko, Gudmar Thorleifsson, Laura J McCulloch, Teresa Ferreira, Harald Grallert, Najaf Amin, Guanming Wu, Cristen J Willer, Soumya Raychaudhuri, Steve A McCarroll, Claudia Langenberg, Oliver M Hofmann, Josée Dupuis, Lu Qi, Ayellet V Segrè, Mandy van Hoek, Pau Navarro, Kristin Ardlie, Beverley Balkau, Rafn Benediktsson, Amanda J Bennett, Roza Blagieva, Eric Boerwinkle, Lori L Bonnycastle, Kristina Bengtsson Boström, Bert Bravenboer, Suzannah Bumpstead, Noël P Burtt, Guillaume Charpentier, Peter S Chines, Marilyn Cornelis, David J Couper, Gabe Crawford, Alex SF Doney, Katherine S Elliott, Amanda L Elliott, Michael R Erdos, Caroline S Fox, Christopher S Franklin, Martha Ganser, Christian Gieger, Niels Grarup, Todd Green, Simon Griffin, Christopher J Groves, Candace Guiducci, Samy Hadjadj, Neelam Hassanali, Christian Herder, Bo Isomaa, Anne U Jackson, Paul RV Johnson, Torben Jørgensen, Wen HL Kao, Norman Klopp, Augustine Kong, Peter Kraft, Johanna Kuusisto, Torsten Lauritzen, Man Li, Aloysius Lieverse, Cecilia M Lindgren, Valeriya Lyssenko, Michel Marre, Thomas Meitinger, Kristian Midthjell, Mario A Morken, Narisu Narisu, Peter Nilsson, Katharine R Owen, Felicity Payne, John RB Perry, Ann-Kristin Petersen, Carl Platou, Christine Proença, Inga Prokopenko, Wolfgang Rathmann, N William Rayner, Neil R Robertson, Ghislain Rocheleau, Michael Roden, Michael J Sampson, Richa Saxena, Beverley M Shields, Peter Shrader, Gunnar Sigurdsson, Thomas Sparsø, Klaus Strassburger, Heather M Stringham, Qi Sun, Amy J Swift, Barbara Thorand, Jean Tichet, Tiinamaija Tuomi, Rob M van Dam, Timon W van Haeften, Thijs van Herpt, Jana V van Vliet-Ostaptchouk, G Bragi Walters, Michael N Weedon, Cisca Wijmenga, Jacqueline Witteman, Richard N Bergman, Stephane Cauchi, Francis S Collins, Anna L Gloyn, Ulf Gyllensten, Torben Hansen, Winston A Hide, Graham A Hitman, Albert Hofman, David J Hunter, Kristian Hveem, Markku Laakso, Karen L Mohlke, Andrew D Morris, Colin NA Palmer, Peter P Pramstaller, Igor Rudan, Eric Sijbrands, Lincoln D Stein, Jaakko Tuomilehto, Andre Uitterlinden, Mark Walker, Nicholas J Wareham, Richard M Watanabe, Goncalo R Abecasis, Bernhard O Boehm, Harry Campbell, Mark J Daly, Andrew T Hattersley, Frank B Hu, James B Meigs, James S Pankow, Oluf Pedersen, H-Erich Wichmann, Inês Barroso, Jose C Florez, Timothy M Frayling, Leif Groop, Rob Sladek, Unnur Thorsteinsdottir, James F Wilson, Thomas Illig, Philippe Froguel, Cornelia M van Duijn, Kari Stefansson, David Altshuler, Michael Boehnke, Mark I McCarthy.
Members of the SAT2D consortium:
Jaspal S Kooner, Danish Saleheen, Xueling Sim, Joban Sehmi, Weihua Zhang, Philippe Frossard, Latonya F Been, Kee-Seng Chia, Antigone S Dimas, Neelam Hassanali, Tazeen Jafar, Jeremy BM Jowett, Xinzhong Li, Venkatesan Radha, Simon D Rees, Fumihiko Takeuchi, Robin Young, Tin Aung, Abdul Basit, Manickam Chidambaram, Debashish Das, Elin Grundberg, Åsa K Hedman, Zafar I Hydrie, Muhammed Islam, Chiea-Chuen Khor, Sudhir Kowlessur, Malene M Kristensen, Samuel Liju, Wei-Yen Lim, David R Matthews, Jianjun Liu, Andrew P Morris, Alexandra C Nica, Janani M Pinidiyapathirage, Inga Prokopenko, Asif Rasheed, Maria Samuel, Nabi Shah, A Samad Shera, Kerrin S Small, Chen Suo, Ananda R Wickremasinghe, Tien Yin Wong, Mingyu Yang, Fan Zhang, Goncalo R Abecasis, Anthony H Barnett, Mark Caulfield, Panos Deloukas, Timothy M Frayling, Philippe Froguel, Norihiro Kato, Prasad Katulanda, M Ann Kelly, Junbin Liang, Viswanathan Mohan, Dharambir K Sanghera, James Scott, Mark Seielstad, Paul Z Zimmet, Paul Elliott, Yik Ying Teo, Mark I McCarthy, John Danesh, E Shyong Tai, John C Chambers.
Conceived and designed the experiments: MAK ST. Performed the experiments: SDR. Analyzed the data: SDR. Contributed reagents/materials/analysis tools: MZIH ASS SB JPO SK AB AHB. Wrote the paper: MAK. Contributed to discussion and reviewed/edited the manuscript: SDR MZIH ASS SB JPO SK ST AB.
- 1. Chaput JP, Despres JP, Bouchard C, Tremblay A (2007) Association of sleep duration with type 2 diabetes and impaired glucose tolerance. Diabetologia 50: 2298–2304.
- 2. Gangwisch JE, Heymsfield SB, Boden-Albala B, Buijs RM, Kreier F, et al. (2007) Sleep duration as a risk factor for diabetes incidence in a large US sample. Sleep 30: 1667–1673.
- 3. Scheer FAJL, Hilton MF, Mantzoros CS, Shea SA (2009) Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA 106: 4453–4458.
- 4. Karlsson B, Alfredsson L, Knutsson A, Andersson E, Toren K (2005) Total mortality and cause-specific mortality of Swedish shift- and dayworkers in the pulp and paper industry in 1952–2001. Scand J Work Environ Health 31: 30–35.
- 5. Karlsson B, Knutsson A, Lindahl B (2001) Is there an association between shift work and having a metabolic syndrome? Results from a population based survey of 27,485 people. Occup Environ Med 58: 747–752.
- 6. Maury E, Moynihan Ramsey K, Bass J (2010) Circadian rhythms and metabolic syndrome: from experimental genetics to human disease. Circ Res 106: 447–462.
- 7. Marcheva B, Moynihan Ramsey K, Buhr ED, Kobayashi Y, Su H, et al. (2010) Disruption of the Clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature 466: 627–631.
- 8. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, et al. (2009) Variants in MTNR1B influence fasting glucose levels. Nat Genet 41: 77–81.
- 9. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42: 105–119.
- 10. Below JE, Gamazon ER, Morrison JV, Konkashbaev A, Pluzhnikov A, et al. (2011) Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. Diabetologia 54: 2047–2055.
- 11. Englund A, Kovanen L, Saarikoski ST, Haukka J, Reunanen A, et al. (2009) NPAS2 and PER2 are linked to risk factors of the metabolic syndrome. J Circadian Rhythms 7: 5.
- 12. Woon PY, Kaisaki PJ, Braganca J, Bihoreau MT, Levy JC, et al. (2007) Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes. Proc Natl Acad Sci USA 104: 14412–14417.
- 14. Garaulet M, Corbalan-Tutau D, Madrid JA, Baraza JC, Parnell LD, et al. (2010) Period2 variants are associated with abdominal obesity, psycho-behavioural factors, and attrition in the dietary treatment of obesity. J Am Diet Assoc 110: 917–921.
- 15. Conlon M, Lightfoot N, Kreiger N (2007) Rotating shift work and risk of prostate cancer. Epidemiology 18: 182–183.
- 16. Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 2056–2062.
- 17. Stevens VL, Ahn J, Sun J, Jacobs EJ, Moore SC, et al. (2010) HNF1B and JAZF1 genes, diabetes, and prostate cancer risk. Prostate 70: 601–607.
- 18. Meyer TE, Boerwinkle E, Morrison AC, Volcik KA, Sanderson M, et al. (2010) Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Cancer Epidemiol Biomarkers Prev 19: 558–565.
- 19. Pierce BL, Ahsan H (2010) Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. Hum Hered 69: 193–201.
- 20. Waters KM, Wilkens LR, Monroe KR, Stram DO, Kolonel LN, et al. (2011) No association of type 2 diabetes risk variants and prostate cancer risk: the multiethnic cohort and PAGE. Cancer Epidemiol Biomarkers Prev 20: 1979–1981.
- 21. Kim S-T, Cheng Y, Tsu F-C, Jin T, Kader AK, et al. (2010) Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic variation. Prostate 70: 1729–1738.
- 22. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, et al. (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40: 638–645.
- 23. Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, et al. (2009) Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res 69: 9315–9322.
- 24. Bellary S, O’Hare JP, Raymond NT, Gumber A, Mughal S, et al. (2008) Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised controlled trial. Lancet 371: 1769–1776.
- 25. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553.
- 26. Rees SD, Hydrie MZI, Shera AS, Kumar S, O’Hare JP, et al. (2011) Replication of thirteen GWA-validated risk variants for type 2 diabetes in Pakistani populations. Diabetologia 54: 1368–1374.
- 27. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al. (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42: 579–589.
- 28. Kooner JS, Saleheen D, Sim X, Sehmi J, Zhang W, et al. (2011) Genome-wide association study in people of South Asian ancestry identifies six novel susceptibility loci for type 2 diabetes. Nat Genet 43: 984–989.
- 29. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
- 30. Zhang EE, Liu Y, Dentin R, Pongsawakul PY, Liu AC, et al. (2010) Cryptochrome mediates circadian regulation of cAMP signalling and hepatic gluconeogenesis. Nat Med 16: 1152–1156.
- 31. Okano S, Hayasaka K, Igarashi M, Iwai H, Togashi Y, et al. (2010) Non-obese early onset diabetes mellitus in mutant cryptochrome1 transgenic mice. Eur J Clin Invest 40: 1011–1017.